Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer

  • Kraipop Wongwaiyut
  • Sakchai Ruangsin
  • Supparerk Laohawiriyakamol
  • Siriporn Leelakiatpaiboon
  • Duangjai Sangthawan
  • Patrapim Sunpaweravong
  • Somkiat SunpaweravongEmail author
Original Research



A multimodality approach using concurrent chemoradiotherapy (CRT) followed by esophagectomy has been the standard treatment in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Computed tomography (CT) is widely utilized to evaluate esophageal cancer before and after CRT. This study evaluated the utility of pretreatment maximal esophageal wall thickness on CT scans to predict treatment outcomes after CRT in patients with locally advanced ESCC.


Eighty-one patients with T3 locally advanced ESCC, whom were treated completely with CRT with and without surgery, and had available CT scans before and after CRT at a university hospital between 2005 and 2015, were retrospectively reviewed.


Twenty patients (24.7%) had esophagectomy after neoadjuvant CRT and sixty-one patients (75.3%) had definitive CRT. The maximal esophageal wall thicknesses were measured retrospectively and correlated with the response and survival after treatment. A total of 40% of neoadjuvant CRT patients achieved a pCR. There was a significant difference in pretreatment maximal esophageal wall thickness between the pCR and non-pCR groups (mean 11.9 ± 5.3 mm versus 16.9 ± 3 mm; p = 0.01). Pretreatment maximal esophageal wall thickness < 10 mm was significantly related to better overall survival than ≥ 10 mm (median survival 79 months versus 15 months; HR 3.21, 95%CI 1.14–9; p = 0.02). The neoadjuvant CRT group had significantly better survival than the definitive CRT group (median survival 51 months versus 14.5 months; HR 0.46; 95%CI 0.25–0.85; p = 0.01).


In our study, pretreatment esophageal wall thickness of T3 locally advanced ESCC is a useful indicator for predicting survival and pCR after treatment.


Chemoradiotherapy Computed tomography (CT) Esophageal cancer Esophagectomy Wall thickness 



We would like to thank David Patterson of the Faculty of Medicine Office of International Relations for his assistance with the English in the manuscript, and Jureerat Saengthong of the Research Unit for helping with statistical analysis in the study.

Funding information

This study was supported by the Faculty of Medicine, Prince of Songkla University.

Compliance with Ethical Standards

This retrospective study was approved by Institutional Ethical Commission Review Board.

Conflict of interests

The author(s) declare no potential conflicts of interest.


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefGoogle Scholar
  2. 2.
    NCCN clinical practice guidelines in oncology; esophageal and esophagogastric junction cancers. Version 1.2019 available from Accessed May 1, 2019. National Comprehensive Cancer Network, Inc.
  3. 3.
    Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus. 2015;12:1–30.CrossRefGoogle Scholar
  4. 4.
    Martin-Richard M, Díaz Beveridge R, Arrazubi V, Alsina M, Galan Guzmán M, Custodio AB, et al. SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol. 2016;18:1179–86.CrossRefGoogle Scholar
  5. 5.
    Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.CrossRefGoogle Scholar
  6. 6.
    Herskovic A, Russell W, Liptay M, et al. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012;23:1095–103.CrossRefGoogle Scholar
  7. 7.
    van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen M, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefGoogle Scholar
  8. 8.
    Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27:660–7.CrossRefGoogle Scholar
  9. 9.
    Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330–7.CrossRefGoogle Scholar
  10. 10.
    Donohoe CL, Reynolds JV. Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. J Thorac Dis. 2017;9:S697–704.CrossRefGoogle Scholar
  11. 11.
    Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.CrossRefGoogle Scholar
  12. 12.
    Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160–8.CrossRefGoogle Scholar
  13. 13.
    Li SH, Rau KM, Lu HI, et al. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3–4 oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg. 2012;42:958–64.CrossRefGoogle Scholar
  14. 14.
    Rice TW. Clinical staging of esophageal carcinoma: CT, EUS, and PET. Chest Surg Clin N Am. 2000;10:471–85.PubMedGoogle Scholar
  15. 15.
    Edge SB, Byrd DR, Compton CC, et al., editors. AJCC cancer Staging Manual. 7th edn. New York: Springer; 2009. p. 103–15.Google Scholar
  16. 16.
    Rizk NP, Seshan VE, Bains MS, et al. Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol. 2007;2:1117–23.CrossRefGoogle Scholar
  17. 17.
    Nomura M, Oze I, Kodaira T, Abe T, Komori A, Narita Y, et al. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis. Int J Clin Oncol. 2016;21:890–8.CrossRefGoogle Scholar
  18. 18.
    Sathornviriyapong S, Matsuda A, Miyashita M, et al. Impact of neoadjuvant chemoradiation on short-term outcomes for esophageal squamous cell carcinoma patients: a meta-analysis. Ann Surg Oncol. 2016;23:3632–40.CrossRefGoogle Scholar
  19. 19.
    Kumbasar B. Carcinoma of esophagus: radiologic diagnosis and staging. Eur J Radiol. 2002;42:170–80.CrossRefGoogle Scholar
  20. 20.
    Kim TJ, Kim HY, Lee KW, et al. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics. 2009;29:403–21.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Kraipop Wongwaiyut
    • 1
  • Sakchai Ruangsin
    • 1
  • Supparerk Laohawiriyakamol
    • 1
  • Siriporn Leelakiatpaiboon
    • 2
  • Duangjai Sangthawan
    • 2
  • Patrapim Sunpaweravong
    • 3
  • Somkiat Sunpaweravong
    • 1
    Email author
  1. 1.Department of Surgery, Faculty of MedicinePrince of Songkla UniversitySongklaThailand
  2. 2.Department of Radiology, Faculty of MedicinePrince of Songkla UniversitySongklaThailand
  3. 3.Department of Internal Medicine, Faculty of MedicinePrince of Songkla UniversitySongklaThailand

Personalised recommendations